United States · Series C startup
8 rounds we have observed, with the 15 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$192Mraised across 8 rounds since 2007, from 8 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
OrbiMed
Domain Associates
Cormorant Asset Management
MPM Capital
Forward Ventures
EcoR1 Capital
Jennison Associates
RMI LLC
Tavistock Life Sciences
Delos Capital
Arrowpoint PartnersFrom a historical funding recordSEC filing: $61M sold, first sale Aug 2015
No investor was named in the report.
From a historical funding recordSEC filing: $24M sold, first sale Jun 2015
No investor was named in the report.
From a historical funding recordSEC filing: $4.9M sold, first sale Sept 2014
No investor was named in the report.
From a historical funding recordSEC filing: $1.3M sold, first sale Jan 2014
Reported by finsmes.comSEC filing: $31M sold, first sale Mar 2013
No investor was named in the report.
From a historical funding recordSEC filing: $9.0M sold, first sale Jan 2010
Reported by onbiovc.comSEC filing: $9.0M sold, first sale Jan 2010
From a historical funding record
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Domain AssociatesMPM CapitalForward VenturesAvalon Ventures
Pappas VenturesRMI LLCOrbiMedFidelityCormorant Asset ManagementEcoR1 CapitalMissing a round, or an investor who was in one? Tell us.
Syndax Pharmaceuticals's investors include Domain Associates, MPM Capital, Forward Ventures, Avalon Ventures and Pappas Ventures, and 10 more on record.
Syndax Pharmaceuticals has raised $192M across 8 rounds since 2007.
Syndax Pharmaceuticals's most recent round was a Series C of $80M in Aug 2015.
Its most recent round, $80M in Aug 2015, is also its largest on record.
Syndax Pharmaceuticals's first round on record, in Apr 2007, was backed by Domain Associates, MPM Capital and Avalon Ventures and 2 others.
Syndax Pharmaceuticals's latest named round is a Series C, in Aug 2015.
Syndax Pharmaceuticals is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States ·